复发多发性骨髓瘤中免疫麻痹的特征与预后影响
该研究纳入258例2008至2015年确诊的复发多发性骨髓瘤患者,评估深度免疫麻痹对复发后生存的预后影响。定性评估显示无、部分和完全免疫麻痹分别占9%、30%和61%。定量免疫麻痹以平均相对差值(ARD)表示,中位ARD为-39%,递归 partitioning 分析确定总生存(OS)最佳截断值为-50%。多变量分析中,定性和定量免疫麻痹均独立影响PFS,但仅定量免疫麻痹对OS有独立预后价值。
要点
- 复发MM中深度免疫麻痹(ARD≤-50%)与更高肿瘤负荷相关。
- 深度免疫麻痹组3年OS为36%,无/浅度组为46%。
- 定量免疫麻痹是复发后OS的独立预后因素。
核心结论
- 在新药和持续治疗时代,复发MM中免疫麻痹深度是复发后生存的重要预后因素。
研究设计与样本
- 回顾性研究纳入258例2008至2015年确诊的复发MM患者,评估免疫麻痹对复发后生存的预后影响。
主要发现
- 定性免疫麻痹:无、部分、完全免疫麻痹分别占9%、30%、61%。
- 中位ARD为-39%,OS最佳截断值为-50%。
- 深度免疫麻痹组3年OS为36%,无/浅度组为46%;2年PFS分别为17%和27%。
- 多变量分析中,定性和定量免疫麻痹均独立影响PFS,仅定量免疫麻痹独立影响OS。
关键数值与推荐
- 定量免疫麻痹以ARD表示,ARD≤-50%定义为深度免疫麻痹。
临床怎么用
- 对复发MM患者可评估免疫麻痹深度(ARD),辅助预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma (MM) is lacking in the current literature. We evaluated 258 patients with relapsed MM, diagnosed from 2008 to 2015, to investigate the prognostic impact of deep immunoparesis on post-relapse survival. On qualitative immunoparesis assessment, no, partial and full immunoparesis was present in 9%, 30% and 61% of patients, respectively. Quantitative immunoparesis was assessed by computing the average relative difference (ARD) between polyclonal immunoglobulin(s) and corresponding lower normal limit(s), with greater negative values indicating deeper immunoparesis. The median ARD was -39%, with an optimal cut-off of -50% for overall survival (OS) by recursive partitioning analysis. Deep immunoparesis (ARD ≤-50%) was associated with a higher tumour burden at first relapse compared to none/shallow [ARD >-50%] immunoparesis. The OS (P = 0·007) and progression-free survival (PFS; P < 0·001) differed significantly between the deep and none/shallow immunoparesis groups. Kaplan-Meier estimates for 3-year OS were 36% and 46%, and for 2-year PFS were 17% and 27%, respectively. On multivariable analysis (MVA) for PFS, both qualitative and quantitative immunoparesis retained negative prognostic impact independently. However, only quantitative immunoparesis was independently prognostic for OS on MVA. Depth of immunoparesis in relapsed MM is an important prognostic factor for post-relapse survival in the era of novel agents and continuous therapy.
引用
- Chakraborty R, Rybicki L, Nakashima MO, et al. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. Br J Haematol. 2020. PMID: 32108328. doi:10.1111/bjh.16488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。